2016 Look-Back in Brain Health: Two Studies with Potential L
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Bexarotene in BEAT-AD
Ever since reports that the cancer therapy bexarotene (Targretin) lowered brain amyloid-?, reduced plaque load and diminished behavioral deficits in mouse models of AD, interest in the agent has been keen.

That interest led to a phase 2a trial known as BEAT-AD, which was conducted at the Lou Ruvo Center for Brain Health among 20 patients aged 50 to 90 with AD confirmed by florbetapir scan. Patients were randomized in a double-blind fashion to four weeks of placebo or bexarotene 300 mg/day.

Results, published in Alzheimer’s Research & Therapy (2016;8:4), were mixed. The trial was negative for one of its primary outcome measures — namely, amyloid burden reduction (as assessed by florbetapir imaging) across the overall sample. But it showed that bexarotene significantly reduced amyloid burden in the subset of patients who were noncarriers of the ApoE4 allele for AD (Figure), which was also a primary prespecified outcome. In this same patient subset, brain amyloid reductions were correlated with increased serum amyloid-?1-42 measurements....

https://consultqd.clevelandclinic.org/2017/01/2016-look-back-brain-health-two-studies-potential-long-term-impact/
Preview
Like
Comment
Share